Research led by Peter Mac is helping explain the broader effects of a new and powerful class of anti-cancer drugs, in the hope of making them work longer for breast cancer patients.
Cyclin-dependent kinase (CDK4/6) inhibitors have become a mainstay of treatment for metastatic breast cancer, though many patients eventually develop resistance.
Studies led by Dr Shom Goel have provided important insights into the broader activity of these drugs, which block key enzymes that breast cancer cells depend on.
“The main effect of these drugs is like a pulling handbrake, such that breast cancer cells stop dividing and enter a paused state that we call ‘senescence’,” says Dr Goel, a consultant oncologist and Group Leader in Peter Mac’s Cancer Research Division.
“Although CDK4/6 inhibitors drugs are very effective, they don’t kill cancer cells and for many patients, their effects can wane over time. There’s a great need to extend the window where these drugs provide good cancer control.”
The preclinical studies demonstrate for the first time that the inhibitor drugs – in addition to blocking cancer cell division – trigger widespread epigenetic changes in breast cancer cells.
For example, the cells developed new ways to avoid cell death (apoptosis) and became more visible to the immune system.
“These epigenetic changes completely transform the way the cancer cells look and behave,” says Dr Goel.
“And this new understanding is important because as the cells change, they develop new vulnerabilities that we can possibly exploit.
“For example, our research supports trialling CDK4/6 inhibitors in combination other treatments – such as immunotherapies or with new therapies designed to trigger cell death – and this could be how we achieve more durable responses.”
The research paper is titled “CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity”, and is published in the journal Nature Cancer. Read the paper in full here
This article originally appeared on the Peter Mac website here. ACRF has granted $10.8 Million to Peter MacCallum for cutting-edge cancer research technology, including one of our three 2020 grants.